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Abstract: Endophytic Streptomyces strains are potential sources for novel bioactive molecules. 
In this study, the diketopiperazine gancidin W (GW) was isolated from the endophytic acti-
nobacterial genus Streptomyces, SUK10, obtained from the bark of Shorea ovalis tree, and it 
was tested in vivo against Plasmodium berghei PZZ1/100. GW exhibited an inhibition rate of 
nearly 80% at 6.25 and 3.125 Mg kg1 body weight on day four using the 4-day suppression test 
method on male ICR strain mice. Comparing GW at both concentrations with quinine hydrochlo-
ride and normal saline as positive and negative controls, respectively, 50% of the mice treated 
with 3.125 Mg kg1 body weight managed to survive for more than 11 months after infection, 
which almost reached the life span of normal mice. Biochemical tests of selected enzymes and 
proteins in blood samples of mice treated with GW were also within normal levels; in addition, 
no abnormalities or injuries were found on internal vital organs. These findings indicated that 
this isolated bioactive compound from Streptomyces SUK10 exhibits very low toxicity and is 
a good candidate for potential use as an antimalarial agent in an animal model.
Keywords: antimalarial, Shorea ovalis, in vivo, endophytic, Streptomyces, gancidin W
Introduction
Malaria is a leading human parasitic disease that increasingly threatens much of the 
world’s population. The emergence of resistance by malarial parasites to currently 
commercially available antimalarial drugs is one of the major factors that lead to 
infection of more than 3 billion people living in high-incidence areas, particularly 
children and the elderly.1,2 Chloroquine resistance is most common in tropical and 
subtropical regions, particularly in Southeast Asia,3,4 and there has also been clinical 
and laboratory evidence of resistance to sulfadoxine, pyrimethamine, artemisinin, 
primaquine, mefloquine and quinine.3,5 Plasmodium falciparum, the most dominant 
causative agent of malaria, has high adaptability, brought about through many types 
of mutations, and has become resistant to nearly all antimalarial drugs.3 Therefore, 
new families of bioactive compounds are needed in order to combat these problems 
and reduce the risk of resistance.
Malaysian tropical forests have not been fully scientifically explored even though 
they are among the oldest on the planet and as many as 1,300 plants are claimed to 
have medicinal properties.6 Previous findings have shown that plants used by the 
Malaysian native population as alternative medicines are actually produced by endo-
phytic microorganisms and may have the potential to treat malaria and many other 
parasitic diseases.7,8 Some of these antibiotic derivatives include alkaloid congeners as 
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potential anticancer and antimicrobial agents;9 nonadecene 
compounds as antifungals10 and antioxidants;11 as well as 
biologically active diketopiperazine (DKP) derivatives.12,13 
DKP derivatives have demonstrated a variety of good bio-
logical activities, such as antibacterial, antiviral, antitumor, 
fungicidal and many more.14,15
Streptomyces, a well-studied genus of gram-positive acti-
nobacteria, shows outstanding chemical and morphological 
diversity with a distinct evolutionary line.15 As these filamen-
tous bacteria have a similar physiology as fungi,16 most Strep-
tomyces spp. have the ability to synthesize various secondary 
metabolites that have numerous medical applications, as 
antibiotic, herbicidal, antiparasitic, antitumor, antifungal and 
enzyme inhibiting agents.17 Producing more than two-thirds 
of clinically useful antibiotics of natural origin,18 endophytic 
Streptomyces spp. have the ability to inhibit a variety of 
human pathogens, including bacteria and fungi.9,19–22
In this work, the DKP gancidin W (GW)23 was isolated 
from the crude extract of an endophytic Streptomyces strain 
designated as SUK10, which was obtained from the bark 
of the Shorea ovalis tree. Screening of GW for antimalarial 
activity against Plasmodium berghei PZZ1/100 strain was 
carried out in order to assess the optimum in vivo antimalarial 
concentration of GW. Assessment of toxicity in terms of 
activity of enzymes in mice blood and total protein determi-
nation, as well as histopathology evaluation of the selected 
vital organs treated with GW, was also carried out.
Materials and methods
Production of crude extract
Nutrient broth (NB) (Sigma-Aldrich, Kuala Lumpur, Malaysia) 
was prepared at pH 7.0. To produce sufficient amount of 
isolates for extraction, five blocks of 5r5 mm International 
Streptomyces Project 2 agar enriched with Streptomyces 
SUK10 were cut and inoculated into 400 mL of autoclaved 
NB at pH 7.0 in a 1,000 mL conical flask. Fermentation was 
carried out using an orbital shaker at 28nC at rotation rate of 
200 rpm for 21 days. By modifying a previous method,22 the 
supernatant was then extracted three times using ethyl acetate 
to obtain 5.2 g of Streptomyces SUK10 crude extract.
,VRODWLRQDQGSXULÀFDWLRQRIELRDFWLYH
compound
Approximately 2.8 g of SUK10 crude extract was fraction-
ated using flash chromatography (Reveleris®; Grace & Co, 
London, UK). The extract was chromatographed over 40 g 
of generic silica and eluted with hexane and ethyl acetate as 
the mobile phases A and B, respectively. The peaks were 
detected under UV light at absorption wavelengths of 245 
and 310 nm coupled to an electron light scattering detector 
(ELSD). A gradient elution was done at 35 mL min1, com-
mencing with 100% hexane:100% ethyl acetate for 80.0 min-
utes, yielding 22 fractions (V1–V22), which were collected 
according to peak response. The purity of the fractions was 
further validated by normal phase thin-layer chromatography. 
Fractions 1–7 were monitored using 80:20 (v/v) of hexane/
ethyl acetate as eluent, fractions 8–13 with 60:40 (v/v) 
hexane/ethyl acetate and fractions 14–22 with 98:2 (v/v) 
dichloromethane/methanol.
,GHQWLÀFDWLRQRIELRDFWLYHFRPSRXQG
All fractions were subjected to nuclear magnetic resonance 
(NMR) spectroscopy in deuterated chloroform (CDCl
3
) for 
one-dimensional (1D) and 2D 1H-NMR analyses (400 MHz). 
Correlation spectroscopy (COSY) (12 scans), heteronuclear 
multiple-quantum coherence (HMQC) (24 scans) and hetero-
nuclear multiple-bond coherence (HMBC) (32 scans) were 
also further implemented for the more purified fractions 11, 
15 and 20. Fraction 15 was also subjected to 13C-NMR and 
distortionless enhancement by polarization transfer (DEPT) 
studies (both 4,000 scans). In addition to the NMR studies, 
liquid chromatography/high-resolution mass spectrometry 
(LC/HRMS) analysis (Accela autosampler; Grace & Co.) 
was also carried out, and the obtained spectral data were 
then compared with AntiBase database.
In vivo antimalarial screening of bioactive 
compound
ICR strain male mice (n120, 25–30 g, 6–8 weeks old) 
were used in all animal experiments and were divided into 
20 groups (n6). All groups were housed in stainless steel 
cages under 12:12 hours with and without light conditions 
at 28nC with daily ad libitum feed. To initiate the infection, 
0.1 mL of 1.0r106 P. berghei PZZ1/100 parasitized red blood 
cell (RBC) solution was intraperitoneously administered into 
the host. To determine the best concentration, 50, 25, 12.5, 
6.25 and 3.125 Mg kg1 bw of GW solutions were prepared 
by dissolving the obtained fractions of GW in 1.0 mL dim-
ethyl sulfoxide (DMSO) as the stock compound solution 
before they were serially diluted with sterile distilled water 
to achieve the targeted concentrations. The 4-day suppression 
test4 was chosen to implement the antimalarial screening, 
whereby day zero of the treatment was the day when the mice 
were treated with 0.1 mL of GW at all concentrations, imme-
diately within 2 hours postinfection. In parallel, 0.1 mL of 
10 mg kg1 bw of dH
2
O-diluted quinine hydrochloride (QH) 
and 0.9% normal saline were respectively used as positive 
control (PC) and negative control (NC) solutions.
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Similarly, successively, day one, day two and day three 
were referred when the same treatment was repeated for the 
next 3 days respectively without any infection. On day four, 
the parasitemia density (%) and inhibition rate (%) were 
calculated by a Giemsa blood smear from the treated and 
control mice using the following expressions:
 
Parasitemia density
Total of  infected red blood cells observed 
Total of  red blood cells observed
r 100
 
and
Inhibition rate
Parasitemia
density of NC
Parasitemia den

¤
¦¥
³
µ´ 
sity
of treated mice
Parasitemia density of NC
¤
¦¥
³
µ´ r100
After 20 days postinfection, the mice were observed daily 
for their survival period (days). Treatment regime with inhi-
bition rate of 65% was considered as having antimalarial 
activity, and the mice group with the longest survival time 
was considered as receiving the best treatment.
In vivo toxicity assessment of the 
compound
Mice with the same characteristics as during antimalarial 
screening (ICR strain, male, 25–30 g, 6–8 weeks old, n36) 
were used for in vivo toxicity assessment. All animal 
experiments for toxicity assessment were conducted under 
the same Universiti Kebangsaan Malaysia Animal Ethics 
Committee (UKMAEC) approval code for antimalarial 
screening. The mice were divided into 12 groups (n6), 
and all groups were subjected to the same conditions (28nC 
room temperature, stainless steel cage, 12:12 hours with and 
without light and daily ad libitum feed). At the best-detected 
concentration during antimalarial screening, toxicity tests 
were carried out on blood samples of mice treated with GW 
according to two types of toxicity regime: acute exposure 
(daily treatment for 7 days) and subacute exposure (daily 
treatment for 28 days). Each toxicity regime was divided into 
two groups of treatment: without infection and immediately 
within 2 hours after infection on day zero. For labeling pur-
poses, all the mice groups were respectively labeled as TA 
for acute exposure without infection, TB (acute exposure 
immediately within 2 hours after infection), TC (subacute 
exposure without infection) and TD (subacute exposure 
immediately within 2 hours after infection). Data from the 
two control regimens, namely, normal mice without any 
infection and treatment (CN) and single-dose infected mice 
(CI), were also obtained for comparison. The animals were 
sacrificed under diethyl ether anesthesia, 0.8–1.0 mL of the 
blood was collected from each mouse by cardiac puncture on 
day eight and day 29 postexposure and tested for serum total 
protein (STP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase (ALP) 
levels; their normal ranges (NRs) were compared with the 
data supplied by Research Animal Resources, University of 
Minnesota, MN, USA.
From the same diethyl ether-anesthetized mice used for 
biochemical toxicity tests, three vital organs, namely, liver, 
kidney and spleen, were individually collected for organ 
toxicity and histology studies. The infiltration procedure was 
done automatically by a tissue processor (Leica EG1169, 
Leica Biosystems [SEA] Pte. Ltd., Singapore). The tissues 
were next embedded in hot paraffin wax using an embedding 
machine (Shandon HistoCentre 2, GMI-Advance, Ramsey, 
MN, USA). These tissues were then cut (0.4–0.6 Mm thick) 
by a microtome (Leica, RM2235). Histologic tissue prepara-
tion was done using hematoxylin-and-eosin (H–E) staining 
method. The H–E-stained slides for organ histology were 
observed using a computerized light microscopic camera 
(Zeiss Primo Star, New York Microscope Co., New York, NY, 
USA, and Dell, Dell Global Business Sdn. Bhd., Selangor, 
Malaysia) at 100r magnification by placing a drop of immer-
sion oil on the surface of the slide or without the immersion 
oil at 40r magnification; this method was vital to give a clear 
picture of the internal structure of the targeted tissues, as well 
as for assessing and identifying abnormalities, toxicity and 
injuries in the tissues.
Ethics statement
The animal protocols used in this study were evaluated 
and approved by the UKMAEC of Universiti Kebangsaan 
Malaysia (UKM) under the given Animal Use Protocol code 
FSK/Biomed/341 and were in accordance with the UKM 
Laboratory Animal Care and Management Guidelines.
Statistical analysis
All results were expressed as the mean o standard deviation 
for every six mice per group (n6). The Shapiro–Wilk test 
was used to determine all of the antimalarial screening and 
toxicity test parameters. Statistical significance was declared 
when the P-value was equal to or less than 0.05 (P0.05).
Results and discussion
After culture optimization, the Streptomyces SUK10 isolate 
produced 10–12 mg of crude dried extract after 21 days of 
fermentation in NB at pH 7.0 and an agitation rate of 200 rpm. 
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As shown in most previous studies,8,20,24–28 biomass production 
was greater at higher agitation speeds. Higher rotating speeds 
during the fermentation process gave better aeration and oxy-
gen could be efficiently supplied to the organisms for their 
growth and metabolism.21,25,27 The fermentation process was 
scaled up to obtain a crude extract with a sufficient yield of 
5.2 g. The crude extract was fractionated, and all 22 fractions 
were subjected to 1H-NMR experiments to determine purity 
and chemical structure. Based on the 1H-NMR analyses, 
fraction V15 was found to contain interesting signals that 
corresponded to the major constituent. V15 at 98% purity 
was isolated at 16.2 mg (0.31% yield) as a light brownish 
solid material with a molecular weight of 210.275 g/mol and 
molecular formula of C
11
H
18
N
2
O
2
, established by LC-high-
resolution electrospray ionization mass spectrometry at a 
retention time of 7.17 minutes. Literature search revealed 
that the 1H- and 13C-NMR data for V15 (Table 1) were in 
accordance to the cyclodipeptide structure for S-prolyl-R-
leucyl-diketopiperazine (Figure 1), previously isolated from 
the sponges Calyx cf. podatypa29 and Callyspongia.30 A simi-
lar compound, named as gancidin W (GW) and elucidated 
as cyclo-(L-leu-L-pro) but with unknown absolute stereo-
chemistry, was earlier isolated from strains of Streptomyces 
gancidus.31,32 In this study, the obtained natural product gave 
an optical rotation of [A]
D
 138.2n (c1.0, EtOH), which 
was compatible with those isolated earlier from other Strep-
tomyces strains.31–34 Therefore, in this study, the nomenclature 
GW was assigned for the isolated compound V15.
With less than 2.0% of parasitemia density, there was 
a significant difference in this parameter (P0.05, n6) 
between 3.125 Mg kg1 bw and the other four concentra-
tions of GW. Nevertheless, in animals given a dose of 
6.25 Mg kg1 bw, 1.43% of parasitemia density was observed, 
which was still far lower (Table 2) than that in animals given 
3.125 Mg kg1 bw concentration. Figure 2 shows the micro-
scopic blood smear from mice treated with 0.1 mL of GW 
at five different concentrations. At 0.1 mL of 10 mg kg1 bw 
of QH administered to the PC group, no infected RBCs were 
found in any of the mice on day four postinfection regardless 
of the tested concentrations. Previous studies4,33,35,36 demon-
strated that no physical side effects were observed in the host 
treated with 10% DMSO. Therefore, it is hypothesized that 
there is no crucial requirement to have 10% DMSO as one 
of our control treatments.
P. berghei PZZ1/100 strain, which is the most established 
and reliable rodent malaria parasite, was used as the infec-
tious agent in this study. This strain was a quinine-sensitive 
and chloroquine-resistant strain,37–39 making QH application 
as a control drug in this study valid and significant. Moreover, 
P. berghei is a rodent malaria parasite that was used to test the 
antimalarial property of the bioactive compound before this 
compound can be introduced in clinical trials.40 Stepniewska 
et al37 documented that in terms of molecular structure, there 
was a similarity between the monomeric structure of lactate 
dehydrogenase from all strains of P. berghei (PbLDH) and 
P. falciparum lactate dehydrogenase (PfLDH). These two 
forms of the enzyme are important in glycolysis because of 
the generation of ATP as an energy source, and they are per-
sistent in the erythrocytes of the host.41–43 This fact proves that 
the mouse model is valid to test in vivo antimalarial activity 
Table 1 Assignment of the 1H- and 13C-NMR signals of GW at 400 MHz in CDCl
3
Position Atom/
molecule 
element
Cyclo-(S-Pro-R-Leu)32
[]]
D
 91#
SUK10-V15 (GW)
[]]
D
 138.2# (c1.0, EtOH)
`
H
 (J in Hz) `
C
`
H
 (J in Hz) `
C
1 C NA 171.4 NA 170.0
2 NA NA NA NA NA
3 CH
2
3.63.5 (m) 45.6 3.63.5 (m) 45.8
4 CH
2
1.941.86 (m), 2.021.99 (m) 22.8 1.941.85 (m), 2.031.96 (m) 23.1
5 CH
2
2.13 (m), 2.33 (m) 28.2 2.11 (m), 2.33 (m) 29.2
6 CH 4.12 (t, J 8.1) 59.1 4.11 (t, J 7.8) 59.3
7 C NA 167.1 NA 166.0
8 NH 5.91 (brs) NA 6.03 (brs) NA
9 CH 4.01 (dd, J 9.4, 3.4) 53.4 4.01 (dd, J 9.2, 3.6) 53.7
10 CH
2
 2.01 (m), 1.52 (ddd, J 14.5, 9.6, 4.9) 38.7 2.02 (m), 1.52 (ddd, J 14.5, 9.6, 5.0) 39.0
11 CH 1.761.69 (m) 24.8 1.791.69 (m) 25.0
12 Me 0.94 (d, J 6.5) 22.8 0.94 (d, J 6.5) 23.0
13 Me 1.00 (d, J 6.5) 21.1 0.98 (d, J 6.5) 22.0
Notes: D
H
 represents the coupling constants (J) for H and D
C
 the coupling constants (J) for C.
Abbreviations: CDCl
3
, deuterated chloroform; EtOH, ethanol; GW, gancidin W; Hz, hertz; NMR, nuclear magnetic resonance; SUK10, endophytic actinobacterial 
Streptomyces strain; s, singlet; d, doublet; t, triplet; m, multiplet; q, quadruplet; br, broad; NA, not applicable.
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using P. berghei as it was also comparable with results from 
infection with P. falciparum in a human study.
A group of scientists discussed the relative merits of a 
range of animal models and their overlap with the complex 
clinical syndromes of human malaria.44,45 These research-
ers agreed that malaria research using male rodents was 
acceptable and understandable and that rodents were 95% 
systemic pathologically, endocrinologically and immuno-
logically reflective of experimental human P. falciparum 
malaria. This was based on the results from a study show-
ing favorable exploitation by the female hormonal system 
when an infectious agent was administered.43 The interfer-
ences from any female hormones in microbiological and 
pathological studies should be considered a bias because the 
results obtained by research would be difficult to analyze. 
Among the research efforts was a study on the new antibiotic 
azithromycin, which has been shown to be effective in male 
mice and monkeys and has undergone a successful trial to 
prevent malaria in humans.43
GW was subjected to antimalarial screening across a 
narrow range of five different concentrations in order to 
determine which dose gave the best antimalarial activity. The 
value for parasitemia density directly reflected the value of 
percentage inhibition, where the higher the percentage inhibi-
tion – the more effective the treatment was.4 The inhibition 
rate at 3.125 Mg kg1 bw dose was found to exhibit the greatest 
value. Reaching almost 80% inhibition rate, there was a sig-
nificant difference (P0.05, n6) between the 3.125 Mg kg1 
bw group and the groups given the other four concentrations. 
Inhibition rate higher than 65%, which was considered a 
benchmark for in vivo antimalarial activity, was also reached 
at 6.25 Mg kg1 bw dose, whereby this value was far better 
than the other three dose concentrations (Table 3).
The survival time of mice treated with 3.125 Mg kg1 bw 
dose of GW was steadily almost twofold longer than that 
of mice given 12.5 Mg kg1 bw and was proportionately 
higher than that for mice given a dose of 6.25 Mg kg1 bw 
(Figure 3). As previously demonstrated, both in vivo and in 
vitro analyses4,14,46–48 predicted that the survival times of the 
treated mice would be longer at a higher parasite inhibition 
rate. The longest period of mouse survival (235.53o 2.20 days) 
was achieved by treatment with GW at a dose concentration 
of 3.125 Mg kg1 bw, which was significantly higher than that 
with other dose concentrations (P0.05, n6). In conjunction 
with this, surprisingly, the remaining 50% (n3) of the group 
treated with GW at this concentration individually managed 
to survive until 291.13o0.5 days postinfection. Based on 
previous documentations,49–53 this period of survival time was 
considered to almost reach the life span of normal male mice 
at approximately 12–18 months. Until 411 postinfection days, 
all PC mice survived and this observation was in parallel 
with results of previous in vivo antimalarial studies,4,14,47,48,52 
while the NC mice survived to 7–9 days postinfection, as 
also recorded in this study.
There was no comparable benchmark found in the litera-
ture for the animals’ survival period in in vivo studies when 
test groups partially had their respective control groups.53 
Therefore, it was not surprising that the survival time at 
12.5 Mg kg1 bw was longer than that at 25 Mg kg1 bw, 
although the inhibition rate at 25 Mg kg1 bw was slightly 
higher. As recommended by the World Health Organiza-
tion (WHO), for every single dose of an antimalarial drug, 
regardless of the type of drug and malaria etiological 
agent, the daily therapeutic dosage in treating malaria was 
5–25 mg kg1 bw for the first month of medication.54,55 This 
dosage was significantly higher than the best concentration 
recorded in this study.
Except for the mice in the TD regime (those immediately 
subjected to subacute exposure within 2 hours after the 
28-day postinfection period), ALT and AST levels slightly 
increased. At the treatment dose of 3.125 Mg kg1 bw, all 
tested enzymes and total protein levels were in their NRs, 
regardless of the type of exposure regime (Table 4). The 
biochemical toxicity test results in this study revealed that 
all of the enzymes and STPs levels for all the regime groups 
were within the NR. However, there was a slightly higher 
average recorded for ALT and AST levels in the mice 
?
?
?
?
??
?
Figure 1 Structure of gancidin W.
Table 2 Parasitemia density (%) of the mice treated with gancidin 
W (GW) compared with positive control (PC) and negative 
FRQWURO1&JURXSVRQGD\IRXUDWÀYHGLIIHUHQWFRQFHQWUDWLRQV
Group Parasitemia density (%)
50# 25# 12.5# 6.25# 3.125#
PC 0 0 0 0 0
NC 6.82o2.7* 7.19o1.8* 6.53o3.2* 5.91o0.7* 7.02o2.2*
GW 3.41o1.9* 2.45o1.3* 2.55o3.3* 1.43o1.8*,a 1.51o2.2*,a
Notes: #Concentration of GW in micrograms per kilogram body weight; *value in 
mean o standard deviation; aVLJQLÀFDQWO\GLIIHUHQWIURPWKHRWKHU*:FRQFHQWUDWLRQ
groups (P0.05, n6, two-way analysis of variance).
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Figure 2 Microscopic thin blood smear of mice treated with GW.
Notes: Mice were treated with 0.1 mL of GW at 50 (A), 25 (B), 12.5 (C), 6.25 (D) and 3.125 Mg kg1 bw (E). The arrows indicate the RBCs infected with Plasmodium berghei 
DWDOOVWDJHVRIWKHSDUDVLWH·VOLIHF\FOHDWWKHWLPHRIPLFHVDFULÀFHLPPDWXUHWURSKR]RLWHULQJVWDJHWURSKR]RLWHVFKL]RQWDQGJDPHWRF\WH0LFURVFRSLFLPDJHVZHUHYLHZHG
at 100rPDJQLÀFDWLRQ
Abbreviations: bw, body weight; GW, gancidin W; RBC, red blood cells.
group that was treated daily with 3.125 Mg kg1 bw of GW 
for 28 days. However, it is too early to conclude that the 
higher levels of ALT and AST in this study for this group 
was due to damaged liver or oversecretion of these enzymes 
into the blood stream. The Department of Research Animal 
Resources, University of Minnesota (MN, USA), circulated 
the guidelines that the values of ALT, AST, ALP and STP can 
vary and be beyond the NR depending on the age, bw, gender 
and the animal model.56 In the mice group receiving a daily 
dose of 3.125 Mg kg1 bw of GW for 4 weeks, the values of 
ALT and AST exceeded the maximum normal values at 3 and 
5 IU L1, respectively. These values were already considered 
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significant because blood was sampled after 28 days post-
treatment, at which time point, the mice were 4 weeks older 
from day 0 of their treatment regime. Most enzymes will be 
oversecreted as the animals mature in age.45 Therefore, the 
normal levels of these enzymes were basically set up accord-
ing to the animal’s age together with other factors mentioned 
herein. Another factor to consider in this study was the ani-
mals’ experimental environment.57,58 Animals (n6) of the 
same gender were housed together in a transparent walled 
box (45r25r25 cm). The animals were situated in a stress 
condition, which induced oversecretion and elevation of ALT 
and AST levels from their NRs. In addition, the mice in this 
group received the treatment daily by the intraperitoneal 
route for 28 days. In an earlier study,57 under similar stress 
conditions, the AST and ALT levels significantly reached a 
twofold increase from the NR.
The selected tissues from all mice in the groups were 
stained with H–E. None of the tissues showed any abnormality, 
including the organs taken from the mice in the TD regime 
group (treated daily with 3.125 Mg kg1 bw of GW for 28 days); 
prior to this, their recorded ALT and AST levels were slightly 
higher than normal. Figures 4–6 show the microscopic H–E 
histology slides for the toxicity assessment of the kidney, 
spleen and liver tissues, respectively, on selected mice treated 
with 3.125 Mg kg1 bw of GW from each of the regime groups. 
Histologically, there was no morphological difference between 
the control and the treatment groups, regardless of whether they 
were administered acute or subacute regimens. At the same 
time, no physical injury or swelling, morphological abnormali-
ties or color changes of the targeted organs were spotted during 
the isolation process from the sacrificed mice.
In this study, the histopathology assessment was observed 
for three vital organs of the mice treated with 3.125 Mg kg1 
bw of GW. Neither in the acute (7 days) nor in the subacute 
(28 days) treatment regime, or in the control treatment groups, 
were activated kupffer cells, cytoplasmic vacuolation and 
sinusoidal dilatation observed by H–E staining of liver, which 
could basically indicate their association with the presence of 
abnormal morphology or toxicity characteristics.59 There was 
no evidence of hepatic injuries in any of the treatment groups 
as they exhibited defined histological structures in their liver 
tissue without any signs of cytoplasmic condensation, mild 
vascular inflammatory changes, congested nuclear changes 
and necrosis.60 Similarly, no presence of granular and cel-
lular cast was noticed in the kidney tissue of all treated and 
Table 3 Inhibition percentage (%) of the mice treated with 
gancidin W (GW) compared with positive control (PC) and negative 
FRQWURO1&JURXSVRQGD\IRXUDWÀYHGLIIHUHQWFRQFHQWUDWLRQV
Group Inhibition percentage (%)
50# 25# 12.5# 6.25# 3.125#
PC 100 100 100 100 100
NC 0 0 0 0 0
GW 50.09o0.1* 65.95o0.3* 60.97o0.5* 75.87o0.8*,a 78.46o0.2*,a,b
Notes: #Concentration of GW in micrograms per kilogram body weight; *value in 
mean o standard deviation; aVLJQLÀFDQWO\GLIIHUHQWIURPWKHRWKHU*:FRQFHQWUDWLRQ
groups (inhibition 65%) at these concentrations; bconcentration 3.125 Mg kg1 bw 
is considered to show the best value for antimalarial activity.
Abbreviation: bw, body weight.
???
???
???
??
???
??
???
???
??
???
??
??
??????????????????????????????
???
??
?? ?? ???? ???? ??????
??
??
Figure 3 Survival period (days) of the mice treated with GW as compared 
WR WKH1& JURXSPLFH DW ÀYH GLIIHUHQW FRQFHQWUDWLRQV REVHUYHG DIWHU  GD\V
postinfection.
Notes: Data presented as mean o standard deviation. Error bars represent standard 
error.
Abbreviations: bw, body weight; GW, gancidin W; NC, negative control.
Table 4 ALT, AST and ALP levels (IU L1), as well as the STP 
level (g dL1), in the mice treated with gancidin W (GW) at 
3.125 Mg kg1 bw under four toxicity regimens
Regime ALT
(IU L1)
AST
(IU L1)
ALP
(IU L1)
STP
(g dL1)
Acute exposure
TA 41.81o2.14* 133.13o2.04* 62.76o2.33* 6.12o2.32*
TB 45.20o1.13* 125.93o2.12* 59.42o2.97* 7.21o3.81*
Subacute exposure
TC 67.57o2.91* 167.76o2.27* 69.29o2.90* 7.93o2.01*
TD 95.03o2.02*,a 212.01o2.33*,b 68.03o2.10* 8.83o3.90*
Control exposure
CN 41.03o3.91* 111.62o1.19* 61.46o2.46* 6.40o1.01*
CI 44.83o1.11* 134.43o4.01* 58.32o2.97* 6.80o3.06*
Indicator
NR 4093 92206 54115 5.89.5
Notes: *Value in mean o standard deviation. aALT level recorded for the mice in 
the TD group, which was slightly higher than the NR. bAST level recorded for the 
mice in the TD group, which was slightly higher than the NR. NR indicates the 
normal range data for ICR strain male mice aged 8 weeks old for the indicator, 
as supplied by Research Animal Resources, University of Minnesota, MN, USA; the 
data present the values under the four toxicity regimens  TA, TB, TC and TD  as 
compared with the control regimens CN and CI. TA, stands for acute exposure 
to gancidin W without infection; TB, acute exposure immediately within 2 hours 
after infection; TC, subacute exposure without infection; TD, subacute exposure 
immediately within 2 hours after infection. CN, normal control mice without any 
infection and treatment; CI, single-dose infected normal mice.
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, 
aspartate aminotransferase; bw, body weight; NR, normal range; STP, serum total 
protein.
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control mice groups regardless of their regime. There was 
also a normal histological structure of the kidney glomerulus 
and tubules, with no glomerular atrophy and tubular necrosis, 
as well as no vascular shrinkage being observed in the renal 
tubules at the cortical zone, which could directly indicate a 
degenerative phenomenon.61,62
The histopathology assessment in the sectional spleen 
tissue in all treatment regimens did not reveal any evi-
dence of vascular changes and periarterial hyperplasia 
of the red pulp and white pulp or malpighian follicle 
nodules. Positively, there was also no proliferation of 
the mononuclear cells around the sinusoid cord structure, 
Figure 4 The microscopic hematoxylin-and-eosin histology slides of kidney for toxicity assessment of selected mice.
Notes: Mice were treated with 3.125 Mg kg1 bw of GW in TA (A), TB (B), TC (C), TD (D), CN (E) and CI (F) groups. TA stands for acute exposure without infection, 
TB stands for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure 
immediately within 2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No signs of toxic effects in 
the kidney were observed for all groups of mice treated with 3.125 Mg kg1 bw of GW. The kidney showed normal cellular structure with intact glomeruli and tubules. There 
was also no sign of necrosis or cellular damage. Microscopic images were viewed at 100rPDJQLÀFDWLRQ
Abbreviations: bw, body weight; GW, gancidin W.
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Figure 5 The microscopic hematoxylin-and-eosin histology slides of spleen for toxicity assessment of selected mice.
Notes: Mice were treated with 3.125 Mg kg1 bw of GW in TA (A), TB (B), TC (C), TD (D), CN (E) and CI (F) groups. TA stands for acute exposure without infection, TB stands 
for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure immediately within 
2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No sign of toxic effects in the spleen were observed 
for all groups of mice treated with 3.125 Mg kg1 bw of GW. Organization of white pulp and red pulp marginal zone was normal. No hypodense splenic lesions, splenomas (a type 
of benign and typically asymptomatic lesion), or tuberous sclerosis were observed for all groups of mice. Microscopic images were viewed at 100rPDJQLÀFDWLRQ
Abbreviations: bw, body weight; GW, gancidin W.
which generally could have activated the accumula-
tion of organic compounds in the blood stream.63,64 No 
shrinkage or deformed size and shape of splenic cord 
that could indicate any spleen degenerative phenomenon 
was evidenced.52 Onkar and Govardhan65 and Rungruang 
et al66 claimed that in the same sacrificed mice, any 
abnormalities spotted and visualized on the four vital 
organs, namely, liver, spleen, lungs and kidney, were also 
histologically recorded by the H–E staining method. In 
this study, concurrently, the selected organs of the mice 
were extracted for histopathology assessment after their 
blood samples were taken for biochemical tests. Because 
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Figure 6 The microscopic hematoxylin-and-eosin histology slides of liver for toxicity assessment of selected mice.
Notes: Mice were treated with 3.125 Mg kg1 bw of GW in TA (A), TB (B), TC (C), TD (D), CN (E) and CI (F) groups. TA stands for acute exposure without infection, 
TB stands for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure 
immediately within 2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No sign of toxic effects in the 
liver were observed for all groups of mice treated with 3.125 Mg kg1 bw of GW. This included structural degeneration of hepatocytes, presence of Kupfer cells, as well as 
LQFUHDVHGQXPEHURIPLWRWLFÀJXUHV7KHKHSDWRF\WHVVHHPHGLQWDFWZKLOHWKHVLQXVRLGVZHUHQRWFRQJHVWHG0LFURVFRSLFLPDJHVZHUHYLHZHGDWrPDJQLÀFDWLRQ
Abbreviations: bw, body weight; GW, gancidin W.
there were no ultimate evidences of blood toxicity in all 
the mice groups, in parallel, similar observations were 
also expected from the histopathology evidences of these 
selected organ tissues of all mice groups. These findings 
showed that GW at 3.125 Mg kg1 bw left no undesired 
effects on the treated host.
Conclusion
Administration of antimalarial drugs totally depends on 
the regime combination, stage of infection, the side effects 
experienced by the infected host and the type of plasmodial 
species.47,52,67,68 Quinine has been proven to kill all Plasmodium 
cells, regardless of the species. However, it is only effective 
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in the early stages of malarial infection, during which gener-
ally, the host will experience asymptomatic signs.69,70 All the 
untreated control mice in this study died between 7 and 9 days 
postinfection, as described in previous in vivo antimalarial 
studies,4,18,51,60,71 regardless of the type of animal model used.
Although GW has been previously reported from other 
Streptomyces species,31,32,34 its antimalarial properties have 
not yet been revealed. In fact, our results indicate that GW is 
one of the metabolites responsible for the in vivo antimalarial 
activity of the ethyl acetate crude extract from SUK10. The 
outcomes of the presented study indicate that Streptomyces 
SUK10 living endophytically in S. ovalis tree is a good 
source of a potential antimalarial agent with relatively very 
low toxicity. Apart from the fact that the progression of the 
erythrocytic cycle in the Plasmodium-infected host is still 
poorly understood,36 there is also a tendency to obtain more 
significant values for certain antimalarial parameters in par-
ticular cycles or stages of the Plasmodium life cycle,43,44,46,54 
which have not been considered in this study.
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